Newly Diagnosed Multiple Myeloma In Patients Who Have Undergone Autologous Stem Cell Transplantation:
Adult: 10 Mg Once Daily For 28 Consecutive Days Of Repeated 28-day Cycles; Increased If Tolerated To 15 Mg Once Daily, After 3 Cycles
Newly Diagnosed Multiple Myeloma In Patients Not Eligible For Transplant (in Combination With Dexamethasone), Multiple Myeloma With Prior Therapy (in Combination With Dexamethasone):
Adult: 25 Mg Once Daily For 21 Consecutive Days Of Repeated 28-day Cycles, For Doses Of Dexamethasone, For Dose Adjustments Due To Side-effects Consult Product Literature
Newly Diagnosed Multiple Myeloma In Patients Not Eligible For Transplant (in Combination With Melphalan And Prednisone):
Adult: 10 Mg Once Daily For 21 Consecutive Days Of Repeated 28-day Cycles For Up To 9 Cycles, Patients Who Complete 9 Cycles Or Are Intolerant To Combination Therapy Should Continue Treatment With Lenalidomide As Monotherapy.
Newly Diagnosed Multiple Myeloma In Patients Not Eligible For Transplant (in Combination With Bortezomib And Dexamethasone):
Adult: 25 Mg Once Daily For 14 Consecutive Days Of Repeated 21-day Cycles For Up To 8 Cycles, Followed By 25 Mg Once Daily For 21 Consecutive Days Of Repeated 28-day Cycles (in Combination With Dexamethasone Alone), For Doses Of Bortezomib And Dexamethasone, For Dose Adjustments Due To Side-effects Consult Product Literature
Myelodysplastic Syndromes:
Adult: 10 Mg Once Daily For 21 Consecutive Days Of Repeated 28-day Cycles.
Mantle Cell Lymphoma:
Adult: 25 Mg Once Daily For 21 Consecutive Days Of Repeated 28-day Cycles.
Content
Cap 10mg /25mg: Lenalidomide 10mg /25mg
Pregnancy
Contraindicated
Stability
Immunosuppressants, Thalidomide and Related Analogues